Notable Labs(NTBL) - 2023 Q4 - Annual Report

Merger and Corporate Structure - Notable Labs completed a merger with Notable Labs, Inc. on October 16, 2023, continuing as a wholly owned subsidiary[17]. - On October 16, 2023, Notable Labs, Inc. merged with Merger Sub, resulting in former Notable Labs, Inc. equity holders owning approximately 71.9% of the outstanding equity of the Company on a fully diluted basis[137]. Predictive Precision Medicines Platform (PPMP) - The Predictive Precision Medicines Platform (PPMP) has achieved a predictive precision of 83-100% in identifying clinically responding patients across four independent clinical validation trials[25]. - The PPMP has a growing data repository of over 190 billion lines of data, derived from patient tissue and blood samples, enhancing its predictive capabilities[30]. - In a study on high-risk myelodysplastic syndromes (MDS), the PPMP demonstrated a positive predictive value (PPV) of 100% for predicting treatment response[35]. - In adult AML studies, the PPMP showed a PPV of 83% for predicting responses to the combination treatment of venetoclax and decitabine[36]. - For pediatric AML, the PPMP achieved a PPV of 100% for predicting minimal residual disease negativity and a PPV of 90% for 1-year relapse-free survival[40]. - The PPMP allows for the identification of patients expected to respond to treatments before initiation, potentially accelerating therapeutic development[19]. - Notable aims to revolutionize predictive precision medicine by expanding the PPMP's reach across various patient segments and diseases[22]. - Notable plans to expand its platform across liquid and solid tumors, focusing on identifying patient populations with high unmet medical needs, where less than 30% respond to standard treatments[41][42]. Drug Development and Clinical Trials - Notable's lead asset, Volasertib, is expected to enter a Phase 2 trial for adult acute myeloid leukemia (AML) in Q2 2024, with results from the first six patients anticipated in Q4 2024[21]. - Volasertib, a PLK-1 inhibitor, has shown clinical activity in approximately 10-30% of patients, with Notable obtaining worldwide rights for its development and commercialization[44][45]. - In a Phase 2 study, Volasertib combined with low-dose cytarabine (V+LDAC) achieved a complete response plus complete response with incomplete blood count recovery rate of 31.0%, compared to 13.3% for LDAC alone[46]. - A follow-up Phase 3 study indicated an overall response rate of 27.7% for V+LDAC versus 17.1% for placebo plus LDAC, suggesting a potential benefit from Volasertib[48]. - Notable plans to initiate a Phase 2 study in relapse/refractory AML in 2024, with a subsequent registrational Phase 3 study contingent on successful outcomes[56][57]. - The company anticipates filing an IND in Q1 2024 and enrolling the first PPMP-selected patient in Q4 2024[57]. - Notable's development strategy for Volasertib includes tailored dosing and improved infection control to enhance clinical tolerability and response rates[51][53]. - In a Phase 1b/2a clinical trial of Fosciclopirox for relapsed or refractory AML, 18 heavily pre-treated patients were enrolled, with 9 evaluable for response assessment; none achieved a complete response, but stable disease was observed in 2 patients[72]. - The PPMP predicted that all patients in the trial would be non-responsive to Fosciclopirox, which was confirmed by actual patient responses, indicating a potential bias in patient selection[73]. Financial Condition and Funding - Notable has incurred significant losses since inception and anticipates continuing to incur substantial losses for the foreseeable future, raising doubts about its ability to continue as a going concern[145]. - The company has generated only limited revenue since inception and does not anticipate significant revenues from product sales for the foreseeable future[152]. - Notable's financial condition and operating results are expected to fluctuate significantly due to various factors, including the transition from research and development to commercial activities[144]. - The company must develop and commercialize drug candidates with significant market potential to achieve profitability, which involves completing clinical trials and obtaining marketing approvals[148]. - Notable's existing cash and capital resources are insufficient to fund all planned efforts, necessitating further funding through various means[159]. - The company expects to incur significant expenses as it continues its research and development efforts, including preclinical and clinical development of its product candidates[146]. - Notable anticipates significant increases in research and development expenses as it advances its product candidates, Volasertib and Fosciclopirox, through clinical trials[160]. - The company expects to require additional capital to support its operations, which may not be available on acceptable terms, potentially impacting its financial condition[159]. - Future sales of Notable's shares could result in dilution for existing shareholders, impacting share price and capital raising efforts[165]. Regulatory Environment - The FDA approval process for new drugs involves extensive regulation and can take many years, requiring substantial data on quality, safety, and efficacy[79]. - Clinical trials are conducted in three phases, with Phase 3 trials designed to provide data necessary for demonstrating product effectiveness and safety[83]. - Post-approval trials may be mandated by the FDA to gather additional safety data after initial marketing approval[84]. - The cost of preparing and submitting a New Drug Application (NDA) is substantial, including application user fees and annual program fees for eligible products[86]. - The FDA aims to complete standard reviews of drug products within ten months and priority reviews within six months[1]. - Upon NDA approval of a new chemical entity, the drug receives five years of marketing exclusivity, preventing the FDA from receiving any ANDA for a generic version during this period[92]. - The FDA may approve a drug under accelerated approval regulations based on a surrogate endpoint that predicts clinical benefit, with rigorous post-marketing compliance requirements[97]. - The centralized procedure for drug approval in the EU has a maximum evaluation timeframe of 210 days, which can be reduced to 150 days under accelerated assessment[105][106]. - Notable's laboratory received its initial CLIA certification in 2018 and was certified by CAP in 2021, ensuring compliance with regulatory standards[110]. - The FDA may require a risk evaluation and mitigation strategy (REMS) as a condition of NDA approval, which can significantly impact the drug's market potential[90]. - The FDA's review process may be extended by three additional months to consider late-submitted information[1]. - The total patent term after extension may not exceed 14 years from approval, with a maximum of five years for a single patent extension[93]. - The Fast Track program allows for more frequent interactions with the FDA and may enable rolling reviews of drug applications[95][96]. - Notable plans to maintain CLIA compliance and certification to ensure eligibility for billing Medicare and Medicaid beneficiaries[111]. - The FDA has not required laboratories that furnish only laboratory developed tests (LDTs) to comply with medical device regulations, but this could change in the future[112]. Market and Competitive Landscape - The pharmaceutical industry presents intense competition, with Notable facing challenges from larger companies with greater resources in research, development, and marketing[65]. - Notable's success is contingent on obtaining and maintaining proprietary protection for its product candidates and preventing infringement by others[74]. - Notable's prospects are heavily reliant on its ability to develop and commercialize drug candidates, which may take several years[171]. - The historical failure rate for drug candidates in the biotechnology industry is high, and Notable has not yet obtained final regulatory approval for any drug candidate[181]. - Notable's drug candidates may not receive marketing approval due to various reasons, including insufficient clinical trial results or failure to meet safety and efficacy standards[179]. - Market acceptance of Notable's drugs is critical for funding future operations, including development and marketing efforts[211]. - Orphan drug designation may provide financial incentives but does not guarantee marketing exclusivity or commercial advantages[212]. - Even with orphan drug designation, Notable may not secure exclusivity if competitors obtain approval first[213]. - The FDA's requirement for demonstrating clinical superiority for orphan drug exclusivity could impact Notable's future approvals[214]. Compliance and Legal Risks - Notable is subject to various healthcare laws and regulations, including the Anti-Kickback Statute and the Stark Law, which could constrain its business operations[120][121]. - The federal False Claims Act imposes civil penalties for presenting false claims, which could apply to Notable even if it does not submit claims directly[123]. - Compliance with data privacy regulations, such as HIPAA and the California Consumer Privacy Act, is essential for Notable's operations and may require significant resources[127][128]. - State and foreign fraud and abuse laws may also apply to Notable's sales and marketing arrangements, adding complexity to compliance efforts[129]. - Non-compliance with regulations could harm Notable's reputation and financial results, necessitating significant resources for compliance efforts[196]. Challenges in Drug Development - Delays in clinical trials can result in increased costs and hinder Notable's ability to generate revenue from its drug candidates[184]. - The company may face challenges in enrolling patients with specific genomic or biomarker signatures necessary for its clinical trials, affecting its research and development efforts[183]. - Notable relies on Contract Research Organizations (CROs) and clinical trial sites for conducting trials, which may not perform as required[187]. - The results of early clinical trials may not predict outcomes in later trials, leading to potential variability in safety and efficacy results[191]. - Any delays in clinical trials could significantly harm Notable's business, financial condition, and prospects[190]. - Notable's drug candidates may face undesirable side effects that could delay or prevent regulatory approval, impacting their commercial profile and leading to significant negative consequences[192]. - If undesirable side effects are identified post-approval, Notable could face market acceptance issues, potential recalls, and increased regulatory restrictions[193]. - Notable is utilizing the PPMP for oncology drug development, but the innovative approach is in early stages, making cost and time predictions challenging[194]. - The PPMP may fail to yield commercially viable drug candidates, affecting Notable's ability to generate future product revenues[195].